aXichem AB (publ) carries out a directed share issue in connection with the exercise of warrants of series TO2A

The Board of Directors of aXichem AB (publ) ("aXichem" or the "Company") has today, based on authorization granted by the Annual General Meeting, resolved on a directed issue of 258,502 shares of class A to qualified investors who have entered into subscription undertakings with the Company in connection with the exercise period for warrants of series TO2A in the Company. The subscription price amounts to SEK 1.50 per share, which corresponds to the exercise price of the warrants of series TO2A. Through the issue, the Company will receive approximately SEK 0.4 million before issue costs.

The Board of Directors of aXichem has today, based on the authorization granted by the Annual General Meeting on 17 June 2026, resolved on a directed issue of 258,502 shares of class A to the three qualified investors Philip Ohlsson, Henrik Amilon and Capital Kin AB, who have entered into subscription undertakings with the Company in connection with the exercise period for warrants of series TO2A in the Company. The subscription undertakings have been utilized as a result of the warrants of series TO2A not having been exercised in full during the exercise period.

As previously communicated by the Company, warrants of series TO2A were exercised for subscription of 8,355,714 shares of class A, corresponding to approximately 97 percent of the total number of outstanding warrants of series TO2A. Through the directed issue now resolved upon, 258,502 shares of class A will be issued, corresponding to the number of shares that would have been subscribed for if the remaining approximately 3 percent of the warrants of series TO2A had been exercised.

The reason for the deviation from the shareholders' preferential rights is to secure that the Company is provided with the capital that would have been provided upon a full exercise of the warrants of series TO2A. The qualified investors have, prior to the exercise period, provided non-compensated subscription undertakings, and the directed issue is carried out in connection with these subscription undertakings being utilized, in order to thereby provide the Company with the remaining capital that would have been provided upon a full exercise of the warrants of series TO2A.

The Board of Directors has considered the possibility of instead raising corresponding capital through an issue with preferential rights for existing shareholders, but assesses that such a solution, taking into account the limited capital need, the time and costs that a preferential rights procedure would entail, as well as the share price risk associated with a more prolonged execution, would not be appropriate or in the interest of the shareholders. A directed issue to the three qualified investors who have provided subscription undertakings instead enables the remaining capital to be provided to the Company in a swift and cost-efficient manner and at the same subscription price as applied for the exercise of the warrants of series TO2A. Against this background, the Board of Directors assesses that the directed issue is the most appropriate alternative for the Company and its shareholders.

The subscription price in the directed issue has been determined through negotiations at arm's length between the Company and the qualified investors, in consultation with the Company's financial advisor and by taking into account a number of market factors. The subscription price amounts to SEK 1.50 per share, which corresponds to the exercise price of the warrants of series TO2A. Against this background, the Board of Directors assesses that the subscription price is in line with market conditions.

Important information

The publication or distribution of this press release may be restricted in certain jurisdictions. Recipients of this press release in the jurisdictions in which this press release has been published or distributed should inform themselves about and comply with such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to acquire or subscribe for any securities in the Company in any jurisdiction.

The information was submitted for publication, through the agency of the contact person set out below, on 23 September 2026, at 10:30 CEST.

Company contact:
Torsten Helsing, CEO, aXichem AB
Phone: +46 40 121 355. Email: torsten.helsing@axichem.com

About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen^® and aXivite^®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: ingredient in animal feed for poultry and ruminants, ingredient in dietary supplements for intestinal health, weight control, sports and exercise, and as an ingredient in dietary supplements for bioavailability enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB. More information is available at www.axichem.com.